H2 Blockers for Gastroesophageal Reflux Disease and Mast Cell Activation Syndrome

Available H2 Blockers and Their Properties

• The American Academy of Pediatrics recommends cimetidine, ranitidine, famotidine, and nizatidine as the main H2 receptor antagonists available for clinical use 1, 2
• Ranitidine is a furan-based H2 blocker that is approximately 7 times more potent than cimetidine with a longer duration of action 3

Clinical Applications

• The American Academy of Pediatrics suggests that all H2 blockers are effective for treating gastroesophageal reflux disease (GERD), particularly milder forms, and abdominal and vascular symptoms in mast cell activation syndrome 1, 2
• H2 blockers work better as prophylactic treatment rather than acute treatment for histamine-mediated conditions, as they prevent histamine from binding to receptors 1

Formulations and Dosing

• The American Academy of Pediatrics recommends typical dosing of cimetidine as 30-40 mg/kg/day divided in 4 doses for pediatric patients 2
• The American Academy of Pediatrics recommends typical dosing of ranitidine as 5-10 mg/kg/day divided in 2-3 doses 2
• The American Academy of Pediatrics recommends typical dosing of famotidine as 1 mg/kg/day divided in 2 doses 2
• The American Academy of Pediatrics recommends typical dosing of nizatidine as 10 mg/kg/day divided in 2 doses 2

Important Clinical Considerations

• H2 blockers can develop tachyphylaxis (reduced effectiveness) within 6 weeks of initiation, limiting their potential for long-term use 2
• H2 blockers with anticholinergic effects (particularly cimetidine) can be associated with cognitive decline, especially in elderly populations 1
• Combining H1 and H2 receptor antagonists provides more comprehensive symptom control than either agent alone for conditions like mast cell activation syndrome 4
• Unlike proton pump inhibitors, famotidine does not interfere with the antiplatelet activity of clopidogrel, making it a potential alternative in patients on dual antiplatelet therapy 5

H2‑Receptor Antagonists: Available Agents and Therapeutically Equivalent Dosing

Available H2‑Blockers

• The four H2‑receptor antagonists approved for clinical use are famotidine, ranitidine, cimetidine, and nizatidine. 6

Therapeutically Equivalent Dosing (based on the cited source)

• The following dosing regimens are considered therapeutically equivalent for the four agents:

• These dose equivalences are derived from the same reference. 6